Repligen Corporation (RGEN) - Total Liabilities
Based on the latest financial reports, Repligen Corporation (RGEN) has total liabilities worth $840.62 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RGEN cash flow conversion to assess how effectively this company generates cash.
Repligen Corporation - Total Liabilities Trend (1985–2024)
This chart illustrates how Repligen Corporation's total liabilities have evolved over time, based on quarterly financial data. Check Repligen Corporation (RGEN) asset resilience to evaluate the company's liquid asset resilience ratio.
Repligen Corporation Competitors by Total Liabilities
The table below lists competitors of Repligen Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kingfa Sci&Tech Co Ltd
SHG:600143
|
China | CN¥42.31 Billion |
|
Guangzhou Friendship Group Co Ltd
SHE:000987
|
China | CN¥163.81 Billion |
|
Nedbank Group Ltd
JSE:NED
|
South Africa | ZAC1.35 Trillion |
|
Gamuda Bhd
KLSE:5398
|
Malaysia | RM19.69 Billion |
|
Wan Hai Lines Ltd
TW:2615
|
Taiwan | NT$137.41 Billion |
|
Zheshang Securities Co Ltd
SHG:601878
|
China | CN¥172.05 Billion |
|
CNOOC Energy Technology & Services Ltd
SHG:600968
|
China | CN¥18.96 Billion |
|
Prestige Estates Projects Limited
NSE:PRESTIGE
|
India | Rs503.31 Billion |
Liability Composition Analysis (1985–2024)
This chart breaks down Repligen Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Repligen Corporation (RGEN) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Repligen Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Repligen Corporation (1985–2024)
The table below shows the annual total liabilities of Repligen Corporation from 1985 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $856.95 Million | +0.44% |
| 2023-12-31 | $853.21 Million | +37.41% |
| 2022-12-31 | $620.90 Million | +2.07% |
| 2021-12-31 | $608.29 Million | +62.76% |
| 2020-12-31 | $373.74 Million | +9.81% |
| 2019-12-31 | $340.35 Million | +113.98% |
| 2018-12-31 | $159.05 Million | +4.70% |
| 2017-12-31 | $151.92 Million | +26.44% |
| 2016-12-31 | $120.15 Million | +411.51% |
| 2015-12-31 | $23.49 Million | +41.83% |
| 2014-12-31 | $16.56 Million | +12.21% |
| 2013-12-31 | $14.76 Million | +14.54% |
| 2012-12-31 | $12.89 Million | +27.58% |
| 2011-12-31 | $10.10 Million | +93.96% |
| 2010-12-31 | $5.21 Million | 0.00% |
| 2009-12-31 | $5.21 Million | -1.74% |
| 2008-12-31 | $5.30 Million | +14.43% |
| 2007-12-31 | $4.63 Million | -2.15% |
| 2006-12-31 | $4.73 Million | +33.79% |
| 2005-12-31 | $3.54 Million | +11.73% |
| 2004-12-31 | $3.17 Million | -4.56% |
| 2003-12-31 | $3.32 Million | +18.17% |
| 2002-12-31 | $2.81 Million | +25.14% |
| 2001-12-31 | $2.24 Million | -15.88% |
| 2000-12-31 | $2.67 Million | +112.18% |
| 1999-12-31 | $1.26 Million | +4.99% |
| 1998-12-31 | $1.20 Million | +199.27% |
| 1997-12-31 | $400.00K | +33.33% |
| 1996-12-31 | $300.00K | -62.50% |
| 1995-12-31 | $800.00K | -94.90% |
| 1994-12-31 | $15.70 Million | +23.62% |
| 1993-12-31 | $12.70 Million | +4.10% |
| 1992-12-31 | $12.20 Million | +64.86% |
| 1991-12-31 | $7.40 Million | +164.29% |
| 1990-12-31 | $2.80 Million | +7.69% |
| 1989-12-31 | $2.60 Million | -23.53% |
| 1988-12-31 | $3.40 Million | +21.43% |
| 1987-12-31 | $2.80 Million | +12.00% |
| 1986-12-31 | $2.50 Million | +38.89% |
| 1985-12-31 | $1.80 Million | -- |
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-pack… Read more